Fig. 1From: Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomasAbsolute lymphocyte count (ALC) at the time of immunotherapy initiation was compared in patients who have demonstrated clinical benefit from pembrolizumab or nivolumab versus patients who have not. Pretreatment ALC was significantly lower in patients who have demonstrated lack of clinical benefit. Data is represented as box-and-whisker plot. *P < 0.05 by unpaired Student’s t-testBack to article page